

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

**Date: November 11<sup>th</sup>, 2025**

To,  
Corporate Relationship Department,  
BSE Limited,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai — 400001

**BSE Scrip Code- 530057**

**Subject: Outcome of the Board Meeting of the Board of Directors held on Tuesday, 11<sup>th</sup> November 2025.**

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors at its meeting held on Tuesday, 11<sup>th</sup> November, 2025, has inter alia considered and approved the following:

1. The Un-Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Limited Review Report(s) issued by the Statutory Auditor for the Quarter ended 30<sup>th</sup> September, 2025.
2. On recommendations received from the Nomination and Remuneration committee, the Board has considered and approved the appointment of CS Chaitra Arora, holding Membership number A78376, as a Company Secretary & Compliance Officer of the Company. **(Annexure-A)**

**Disclosure under Regulation 30 of SEBI Listing Regulations, read with Clause 7 of Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as (Annexure-A)**

3. To take note of the Resignation of CS Siddhi Shah (Membership number A44885), from the position of Company Secretary & Compliance Officer of the Company with effect from 26<sup>th</sup> September, 2025. **(Annexure-B)**
4. Considered and approved alteration of the main object clause of the memorandum of association of the company, subject to necessary approvals.
5. Disclosure under Regulation 30 of SEBI Listing Regulations, read with Clause 7 of Para A of Part A of Schedule III of SEBI Listing Regulations and with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as. **(Annexure-C)**
6. Considered, approved and recommended an alteration in the Object Clause of the Memorandum of Association (MOA) of the Company to expand the business scope to

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

---

include manufacturing, processing, trading, and distribution of plastic polymer films, plastic bags, paper bags for packaging, and flexible packaging materials for various industrial and consumer applications, subject to the approval of the shareholders of the Company through Postal Ballot.

7. Considered and approved the Calendar of events for the purpose of the Postal Ballot of the Company. The Calendar of events for the postal ballot of the company is annexed herewith and marked as **(Annexure-D)**
8. Considered and approved the Notice of Postal Ballot process of the Company
9. Considered and approved, November 7<sup>th</sup>, 2025, as the Cut-off date for ascertaining the list of Shareholders to whom notice of the Postal Ballot shall be sent and for reckoning voting rights.
10. Appointment of Mr. Chintan K. Patel, Practicing Company Secretary (Membership No: A31987, COP: 11959) as Scrutinizer to scrutinize e-voting in a fair and transparent manner.

Details as required under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, in relation to the alteration of the main object clause of the memorandum of association of the company, is provided in **Annexure-C**.

The meeting of the Board of Directors of the Company commenced at 4:00 P.M. and concluded at 4:45 P.M.

You are requested to kindly take the same on record and acknowledge.

Thanking You.

**For Vivanza Biosciences Limited**

---

**Jayendra Mehta**  
**Managing Director**  
**DIN: 08210602**

Encl:As above

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015

## Annexure - A

Sr. No.	Details of events that need to be provided	Information on such event(s)
1.	Reason for change viz. appointment, <del>resignation, removal, death, or otherwise;</del>	CS Chaitra Arora has been appointed as the Whole Time Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company.
2.	Date of Appointment / <del>Cessation</del>	November 11 <sup>th</sup> , 2025
3.	Brief profile (in case of appointment)	CS Chaitra Arora is an Associate Member of the Institute of Company Secretaries of India and has experience in company law, SEBI regulations, and IPO due diligence. Equipped with good drafting skills and practical knowledge of corporate governance, compliance, and regulatory filings, dealing with matters of the Companies Act and allied laws.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015

## Annexure – B

Sr. No.	Details of events that need to be provided	Information on such event(s)
1.	Reason for change viz. <del>appointment</del> , resignation, removal, <del>death, or otherwise;</del>	Resignation of Ms. Siddhi Shah as the Company Secretary and Compliance Officer due to personal reasons, such as better prospects and furtherance of her career.
2.	Date of <del>appointment</del> /cessation	Letter dated 26 <sup>th</sup> September, 2025, effective from the closing of business hours on 26 <sup>th</sup> September, 2025
3.	Brief profile (in case of appointment)	Not Applicable.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.
5.	Information as required under BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018	Not Applicable.
6.	Letter of Resignation along with a detailed reason for resignation	Attached

Date: 26<sup>th</sup> September, 2025

To,  
The Board of Directors  
**Vivanza Biosciences Limited**  
403, Sarthik 2,  
Opp. Rajpath Club,  
S. G. Highway, Ahmedabad 380054

**Subject: Resignation from the post of Company Secretary & Compliance Officer**

Dear Sir,

I hereby tender my resignation from the position of Company Secretary & Compliance Officer as Key Managerial Personnel (KMP) in the Vivanza Biosciences Limited ("Company") with effect from the closing of business hours on 26<sup>th</sup> September, 2025 to pursue career opportunity outside the Company.

Further, I confirm that there is no material reason for my resignation apart from the reason mentioned above.

I would like to take this opportunity to offer my sincere gratitude to the Board of Directors, CFO, senior management, colleagues and my team for the unstinted support & co-operation extended to me during my tenure to perform my duties and responsibilities.

Please acknowledge the receipt of my Resignation Letter.

Thanking You,  
Yours faithfully,



**Siddhi Shah**

**Company Secretary & Compliance Officer**

ICSI Membership No: ACS 44885

EC&IN: RA044885F000094594

Accepted.

  
26/9/25

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

---

Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015

## **Annexure – C**

The “Main Object” clause of the MOA of the Company is being amended by inserting a new sub-clause 7 after the existing sub-clause 6 of Clause III (A). The Amendment shall be effective upon the registration of the resolution with the Registrar of Companies. The proposed change of the object clause requires the approval of shareholders through a Special Resolution pursuant to the provisions of Section 13 of the Companies Act, 2013.

### **Objects Clause :**

“To carry on the business of manufacturing, processing, producing, and dealing in plastic polymer films of 25 microns thickness, plastic bags and sacks made from polyethylene (PE), polypropylene (PP), and other plastic polymers, paper bags for packaging with or without plastic coating or lamination, and all forms of flexible packaging materials suitable for food, chemicals, fertilizers, grains, and consumer goods packaging; to trade, supply, and distribute such manufactured products domestically and internationally; to procure and import raw materials and packaging inputs required for the above manufacturing; to undertake research and development for product improvement and innovation; to obtain and hold necessary patents, licenses, and regulatory approvals; to establish and maintain manufacturing units, warehouses, and distribution centers; and to undertake all ancillary, incidental, and allied activities in support of the above business operations including financial management, statutory compliance, and general administration.”

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

## Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015

### Annexure – D

#### CALENDAR OF EVENTS

Sr. No.	Particulars	Date
1	Date of appointment of the scrutinizer	11/11/2025
2	Benpos Date for Sending Notice	07/11/2025
3	Cut-off date to record the entitlement of the shareholders to cast their vote electronically (date should not be earlier than 7 days before EOGM)	07/11/2025
4	Date of completion of <b>dispatch</b> of notice, including the process and manner for voting by electronic means	14/11/2025
5	Date and time of commencement of voting through electronic means	17/11/2025 Morning 9 AM
6	Date and time of the end of voting through electronic means	16/12/2025 Evening 5 PM
7	Submission of the Report by the Scrutinizer	17/12/2025
8	Date and Time of EOGM	NA
9	Date of declaration of the result by the Chairman	Upto 18/12/2025
10	Book Closure period/ Record date	NA
11	Scrutinizer Name, email ID, and PAN No.	<b>Name: Patel &amp; Associates</b> <b>Email ID: <a href="mailto:cschintanpatel@gmail.com">cschintanpatel@gmail.com</a></b> <b>PAN: AOEPP9125P</b>
12	Dividend (No) If Yes, please mention Rs.____ per share	<b>NA</b>

### For Vivanza Biosciences Limited

JAYENDRA  
AMICHAND MEHTA  
AMICHAND MEHTA  
Date: 2025.11.11 16:09:29  
+05'30'

**Jayendra Mehta**  
**Managing Director**  
**DIN: 08210602**

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To  
The Board of Directors,  
Vivanza Biosciences Limited

2

We have reviewed the accompanying statement of unaudited financial results of Vivanza Biosciences Limited for the quarter ended 30.09.2025 attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, SHIVAM SONI & Co.  
Chartered Accountants  
FRN: 152477W



*Shivam*

CA Shivam Soni  
Proprietor  
Membership No: 178351  
UDIN : 25178351BMIRQC6556

Place: Ahmedabad  
Date: 11<sup>th</sup> November, 2025

## VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025.

(Rs. in Lacs except per share data)


Particulars	Quarter Ended			Six Month Ended		Year Ended
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income from Operations</b>						
(a) Revenue from operations	5373.18	782.06	158.33	6155.24	201.11	294.28
(b) Other Income	0.76	1.74	0.19	2.50	0.51	3.46
<b>Total Income</b>	<b>5373.93</b>	<b>783.81</b>	<b>158.52</b>	<b>6157.74</b>	<b>201.62</b>	<b>297.74</b>
<b>2 Expenses</b>						
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	5516.01	770.95	142.11	6286.96	174.24	266.77
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-213.44	-15.63	-4.52	-229.07	-44.93	-4.29
(d) Employee benefits expense	15.98	9.22	8.74	25.20	18.10	36.73
(e) Finance Cost	4.71	7.66	9.15	12.37	18.44	35.08
(f) Depreciation and amortisation expense	0.35	0.35	0.41	0.71	0.71	1.40
(g) Other expenses	4.11	9.40	2.10	13.52	11.88	31.42
<b>Total Expenses</b>	<b>5327.72</b>	<b>781.95</b>	<b>157.99</b>	<b>6109.68</b>	<b>178.44</b>	<b>367.10</b>
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	<b>46.21</b>	<b>1.86</b>	<b>0.53</b>	<b>48.06</b>	<b>23.18</b>	<b>-69.36</b>
<b>4 Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>5 Profit/(Loss) before tax (3-4)</b>	<b>46.21</b>	<b>1.86</b>	<b>0.53</b>	<b>48.06</b>	<b>23.18</b>	<b>-69.36</b>
<b>6 Tax Expense</b>						
(a) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.14
<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.14</b>
<b>7 Profit / (Loss) for the period from continuing oprations (5-6)</b>	<b>46.21</b>	<b>1.86</b>	<b>0.53</b>	<b>48.06</b>	<b>23.18</b>	<b>-69.51</b>
<b>8 Profit (Loss) from discontinuing oprations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9 Tax Expense of discontinuing oprations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>10 Profit (Loss) from discontinuing oprations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>11 Other Comprehensive Income</b>						
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income for the period</b>	<b>46.21</b>	<b>1.86</b>	<b>0.53</b>	<b>48.06</b>	<b>23.18</b>	<b>-69.51</b>
<b>13 Paid-up equity share capital (Face value of Rs. 1/- each)</b>	<b>400</b>	<b>400</b>	<b>400</b>	<b>400</b>	<b>400</b>	<b>400</b>
<b>14 Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>71.53</b>
<b>15 Earnings Per Share (before extraordinary items) (not annualised):</b>						
(a) Basic	0.12	0.0046	0.00	0.12	0.06	-0.17
(b) Diluted	0.12	0.0046	0.00	0.12	0.06	-0.17
<b>16 Earnings Per Share (after extraordinary items) (not annualised):</b>						
(a) Basic	0.12	0.0046	0.00	0.12	0.06	-0.17
(b) Diluted	0.12	0.0046	0.00	0.12	0.06	-0.17

**Notes:**

1. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on November 11, 2025. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended September 30, 2025.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities

	
	
	<b>JAYENDRA MEHTA</b> <b>MANAGING DIRECTOR</b> DIN : 08210602
Date : 11/11/2025	
Place : Ahmedabad	

<b>VIVANZA BIOSCIENCES LIMITED</b>		
<b>STATEMENT OF STANDALONE ASSETS AND LIABILITIES</b>		
(Rs.in Lacs)		
Particulars	As at 30/09/2025	As at 31/03/2025
<b>A</b>	<b>ASSETS</b>	
	<b>1 Non-current Assets</b>	
(a)	Property , Plant and Equipment	1.35
(b)	Other Intangible assets	2.06
(c)	Capital work in progress	-
(d)	Intangible assets under development	-
(e)	<b>Financial Assets :</b>	
(i)	Investments	191.45
(ii)	Deferred tax assets (Net)	191.45
(iii)	Loans	0.06
(f)	Other non-current assets	-
	<b>Sub-total - Non-current Assets</b>	<b>59.33</b>
	<b>2 Current Assets</b>	<b>252.20</b>
(a)	Inventories	59.33
(b)	<b>Financial Assets :</b>	
(i)	Investments	413.32
(ii)	Trade Receivables	184.25
(iii)	Cash and Cash Equivalents	-
(iv)	Loans	-
(c)	Other current assets	3,232.18
	<b>Sub-total - Current Assets</b>	<b>55.38</b>
	<b>TOTAL - ASSETS</b>	<b>4,260.93</b>
		<b>1,138.31</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>	
	<b>Shareholders' Funds</b>	
(a)	Share Capital	400.00
(b)	Other Equity	400.00
	<b>Sub-total - Shareholders' Funds</b>	<b>50.10</b>
		<b>2.04</b>
		<b>450.10</b>
		<b>402.04</b>
	<b>1 Liabilities</b>	
	<b>Non-current Liabilities</b>	
(a)	<b>Financial Liabilities :</b>	
(i)	Borrowings	77.53
(b)	Deferred Tax Liabilities (Net)	77.53
(c)	Provisions	-
(d)	Other Non - Current Liabilities	-
	<b>Sub-total - Non-current liabilities</b>	<b>-</b>
	<b>2 Current Liabilities</b>	<b>77.53</b>
(a)	<b>Financial Liabilities :</b>	
(i)	Borrowings	650.72
(ii)	Trade Payables	531.73
(iii)	Other Financial Liabilities	3213.26
(b)	Provisions	-
(c)	Other Current Liabilities	1.39
	<b>Sub-total - Current Liabilities</b>	<b>120.15</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>3,985.51</b>
		<b>911.65</b>
		<b>4,513.13</b>
		<b>1,391.22</b>



*G. S. S.*

**VIVANZA BIOSCIENCES LIMITED**

**Cashflow Statement**

Particulars	(Rs.in Lacs)	
	01-04-2025 to 30-09-2025	01-04-2024 to 31-03-2025
<b>A Cash flow from Operating Activities</b>		
Net Profit Before Tax	48.06	(69.36)
Adjustments for:		
Add Depreciation	0.71	1.40
Less Dividend Income	-	-
Add Interest Expense	12.37	35.08
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	<u>61.14</u>	<u>(32.89)</u>
Adjustments for:		
Increase/(Decrease) in Trade Payables	2,891.45	(501.67)
Increase/(Decrease) in Other Current Liabilities	65.82	12.03
Increase/(Decrease) in Provisions	(2.41)	(19.73)
(Increase)/Decrease in Trade Receivables	(2,493.59)	298.08
(Increase)/Decrease in short term loans & advances	2.30	-
Increase/(Decrease) in Borrowing	-	-
(Increase)/Decrease in inventories	(229.07)	(4.29)
(Increase)/Decrease in other current assets	(351.84)	1.57
<b>Cashflow generated from Operating Activities</b>	<u>(56.20)</u>	<u>(246.88)</u>
Income Tax Paid ( Net of Refund)	-	-
<b>Net Cashflow generated from Operating Activities A</b>	<u>(56.20)</u>	<u>(246.88)</u>
<b>B Cash flow from Investment Activities</b>		
Purchase of Property , Plant and Equipment	-	(0.79)
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
<b>Net Cashflow generated from Investments Activities B</b>	<u>-</u>	<u>(0.79)</u>
<b>C Cash flow from Financing Activities</b>		
Interest Expenses	(12.37)	(35.08)
(Increase)/Decrease in other non-current assets	0.00	-
(Increase) /Decrease in Long term Loans & Advances (Assets)	-	(4.34)
Increase /(Decrease) in Borrowings (Liabilities)	119.00	282.98
Increase/(Decrease) in non current liabilities	-	-
Increase/(Decrease) in other financial liabilities	-	-
<b>Net Cashflow generated from Financing Activities C</b>	<u>106.63</u>	<u>243.55</u>
<b>Net Change in Cash &amp; Cash Equivalents (A+B+C)</b>	<u>50.44</u>	<u>(4.11)</u>
Opening Cash & Cash Equivalents	4.94	9.05
<b>Closing Cash &amp; Cash Equivalents</b>	<u>55.38</u>	<u>4.94</u>



# SHIVAM SONI & CO. Chartered Accountants

Address : 802, Swati Clover, Nr. Shilaj Circle, Thaltej - Bopal Road, Ahmedabad - 380058  
Phone : +91 94095 19080 E-mail : ca.shivam94@gmail.com

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To  
The Board of Directors,  
Vivanza Biosciences Limited

We have reviewed the accompanying statement of unaudited consolidated financial results (the 'Statement') of Vivanza Biosciences Limited (the 'Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended 30 September 2025 and the consolidated year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), Prescribed under section 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI



(Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Statement includes the interim financial information of Vivanza Lifesciences Private Limited (The Subsidiary Company), which have been reviewed / audited by their auditors, and have been furnished to us by the Holding Company's management. Our Conclusion on the Statement, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular, in so far as it relates to the aforesaid subsidiaries are based solely on such audited / reviewed interim financial information.

Our conclusion is not modified in respect of this matter.



Place: Ahmedabad  
Date: 11<sup>th</sup> November, 2025

For, SHIVAM SONI & Co.  
Chartered Accountants  
FRN: 152477W

*Shivam*

CA Shivam Soni  
Proprietor  
Membership No: 178351  
UDIN : 25178351BMIRQB3154

## VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
CIN : L24110GJ1982PLC005057

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025.

(Rs. in Lacs except per share data)


Particulars	Quarter Ended			Six Month Ended		Year Ended
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income from Operations</b>						
(a) Revenue from operations						
(b) Other Income	5535.78	893.92	300.06	6429.70	543.98	742.33
<b>Total Income</b>	0.76	1.74	0.19	2.50	0.51	6.15
<b>2 Expenses</b>	5536.53	895.66	300.25	6432.20	544.49	748.48
(a) Cost of Materials consumed						
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	5599.44	961.25	282.43	6560.69	512.69	707.74
(d) Employee benefits expense	-155.71	-105.50	-11.03	-261.21	-58.94	-25.68
(e) Finance Cost	24.82	13.64	13.73	38.46	28.99	57.51
(f) Depreciation and amortisation expense	4.71	7.66	9.15	12.37	18.44	35.14
(g) Other expenses	0.35	0.35	0.41	0.71	0.71	1.40
<b>Total Expenses</b>	6.63	9.57	4.01	16.20	14.47	38.94
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	5480.24	886.96	298.70	6367.22	516.36	815.05
4 Exceptional Items	56.29	8.70	1.55	64.98	28.13	-66.57
<b>5 Profit/(Loss) before tax (3-4)</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>6 Tax Expense</b>	56.29	8.70	1.55	64.98	28.13	-66.57
(a) Current tax						
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.70
<b>Total Tax Expenses</b>	0.00	0.00	0.00	0.00	0.00	0.14
<b>7 Profit / (Loss) for the period from continuing operations (5-6)</b>	0.00	0.00	0.00	0.00	0.00	0.84
<b>8 Profit (Loss) from discontinuing operations</b>	56.29	8.70	1.55	64.98	28.13	-67.41
<b>9 Tax Expense of discontinuing operations</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>10 Profit (Loss) from discontinuing operations (after tax)(8-9)</b>	0.00	0.00	0.00	0.00	0.00	0.00
11 Share of Profit / ( Loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
12 Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
<b>13 Other Comprehensive Income</b>	0.00	0.00	0.00	0.00	0.00	0.00
A(i) Items that will not be reclassified to profit or loss						
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>Other Comprehensive Income for the period</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>14 Total Comprehensive Income for the period</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>15 Total Comprehensive Income attributable to :</b>	56.29	8.70	1.55	64.98	28.13	-67.41
Share of Profit / ( Loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
<b>16 Paid-up equity share capital (Face value of Rs. 10/- each)</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>17 Other Equity</b>	400	400	400	400	400	400
<b>Earnings Per Share (before extraordinary items) (not annualised):</b>						-3.59
(a) Basic						
(b) Diluted	0.14	0.02	0.00	0.16	0.07	-0.17
<b>Earnings Per Share (after extraordinary items) (not annualised):</b>						-0.17
(a) Basic						
(b) Diluted	0.14	0.02	0.00	0.16	0.07	-0.17

**Notes:**

1. The above Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on November 11, 2025. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended September 30, 2025.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities.



For, VIVANZA BIOSCIENCES LIMITED

*Jayendra Mehta*  
**JAYENDRA MEHTA**  
MANAGING DIRECTOR  
DIN : 08210602

Date : 11/11/2025  
Place : Ahmedabad

<b>VIVANZA BIOSCIENCES LIMITED</b>			
<b>STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES</b>			
(Rs.in Lacs)			
Particulars	As at 30/09/2025	As at 31/03/2025	
<b>A</b>	<b>ASSETS</b>		
	<b>1 Non-current Assets</b>		
(a)	Property , Plant and Equipment	69.18	69.88
(b)	Other Intangible assets	3.00	163.54
(c)	Capital work in progress	-	-
(d)	Goodwill	160.54	-
(e)	Intangible assets under development	-	-
(f)	<b>Financial Assets :</b>		
(i)	Investments	0.25	0.25
(ii)	Deferred tax assets (Net)	0.06	0.06
(iii)	Loans	104.83	113.82
(g)	Other non-current assets	59.33	59.33
	<b>Sub-total - Non-current Assets</b>	<b>397.20</b>	<b>406.89</b>
	<b>2 Current Assets</b>		
(a)	Inventories	487.52	226.31
(b)	<b>Financial Assets :</b>		
(i)	Investments	-	-
(ii)	Trade Receivables	3467.78	805.93
(iii)	Cash and Cash Equivalents	60.12	11.69
(iv)	Loans	180.77	164.35
(c)	Other current assets	381.97	30.15
	<b>Sub-total - Current Assets</b>	<b>4,578.15</b>	<b>1,238.43</b>
	<b>TOTAL - ASSETS</b>	<b>4,975.35</b>	<b>1,645.32</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Shareholders' Funds</b>		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	61.39	(3.59)
	<b>Sub-total - Shareholders' Funds</b>	<b>461.39</b>	<b>396.41</b>
	<b>1 Liabilities</b>		
	<b>Non-current Liabilities</b>		
(a)	<b>Financial Liabilities :</b>		
(i)	Borrowings	362.51	333.49
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	<b>Sub-total - Non-current liabilities</b>	<b>362.51</b>	<b>333.49</b>
	<b>2 Current Liabilities</b>		
(a)	<b>Financial Liabilities :</b>		
(i)	Borrowings	650.72	531.73
(ii)	Trade Payables	3375.60	261.81
(iii)	Other Financial Liabilities	0.00	-
(b)	Provisions	4.97	5.91
(c)	Other Current Liabilities	120.16	115.97
	<b>Sub-total - Current Liabilities</b>	<b>4,151.45</b>	<b>915.42</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>4,975.35</b>	<b>1,645.32</b>



*Handwritten signature*

**VIVANZA BIOSCIENCES LIMITED****Cashflow Statement**

(Rs.in Lacs)

Particulars	01-04-2025 to 30-09-2025	01-04-2024 to 31-03-2025
<b>A Cash flow from Operating Activities</b>		
Net Profit Before Tax	64.98	(66.57)
Adjustments for:		
Add Depreciation	0.71	1.40
Less Dividend Income	-	-
Add Interest Expense	12.37	35.14
Less Short Term Capital Gain (Mutual Fund)	-	-
<b>Operating Profit / (Loss) before Working Capital Changes</b>	<b>78.06</b>	<b>(30.03)</b>
Adjustments for:		
Increase/(Decrease) in Trade Payables	3,113.78	(561.66)
Increase/(Decrease) in Other Current Liabilities	4.19	(1.31)
Increase/(Decrease) in Provisions	(0.94)	(22.71)
(Increase)/Decrease in Trade Receivables	(2,661.85)	348.01
(Increase)/Decrease in short term loans & advances	(16.42)	(31.58)
Increase/(Decrease) in Borrowing	118.99	65.29
(Increase)/Decrease in inventories	(261.21)	(25.68)
(Increase)/Decrease in other current assets	(351.82)	10.45
<b>Cashflow generated from Operating Activities</b>	<b>22.79</b>	<b>(249.21)</b>
Income Tax Paid ( Net of Refund)	-	0.70
<b>Net Cashflow generated from Operating Activities A</b>	<b>22.79</b>	<b>(249.91)</b>
<b>B Cash flow from Investment Activities</b>		
Purchase of Property , Plant and Equipment		(0.80)
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
<b>Net Cashflow generated from Investments Activities B</b>	<b>-</b>	<b>(0.80)</b>
<b>C Cash flow from Financiag Activities</b>		
Interest Expenses	(12.37)	(35.14)
(Increase)/Decrease in other non-current assets	-	-
(Increase) /Decrease in Long term Loans & Advances (Assets)	8.99	-2.12
Increase /(Decrease) in Borrowings (Liabilities)	29.02	282.97
Increase/(Decrease) in non current liabilities	-	-
Increase/(Decrease) in other financial liabilities	-	-
<b>Net Cashflow generated from Financing Activities C</b>	<b>25.64</b>	<b>245.70</b>
<b>Net Change in Cash &amp; Cash Equivalent (A+B+C)</b>	<b>48.43</b>	<b>(5.01)</b>
Opening Cash & Cash Equivalents	11.69	16.69
<b>Closing Cash &amp; Cash Equivalents</b>	<b>60.12</b>	<b>11.69</b>

